Business Description
Mercury Laboratories Ltd
ISIN : INE947G01011
Total Employee Number:
503Compare
Compare
Traded in other countries / regions
538964.India IPO Date
2015-02-23Description
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and Internationally, of which key revenue is derived from sales made in India.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.76 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.91 | |||||
Interest Coverage | 8.74 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.38 | |||||
Beneish M-Score | -1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.3 | |||||
3-Year EBITDA Growth Rate | 2 | |||||
3-Year EPS without NRI Growth Rate | -4.9 | |||||
3-Year FCF Growth Rate | -8.3 | |||||
3-Year Book Growth Rate | 8.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.74 | |||||
9-Day RSI | 51.23 | |||||
14-Day RSI | 50.82 | |||||
3-1 Month Momentum % | 2.58 | |||||
6-1 Month Momentum % | 0.77 | |||||
12-1 Month Momentum % | -11.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.85 | |||||
Quick Ratio | 3.24 | |||||
Cash Ratio | 0.55 | |||||
Days Inventory | 92.18 | |||||
Days Sales Outstanding | 126.36 | |||||
Days Payable | 96.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.45 | |||||
Dividend Payout Ratio | 0.09 | |||||
Forward Dividend Yield % | 0.45 | |||||
5-Year Yield-on-Cost % | 0.57 | |||||
Shareholder Yield % | -1.88 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.55 | |||||
Operating Margin % | 6.2 | |||||
Net Margin % | 5.65 | |||||
EBITDA Margin % | 12.62 | |||||
FCF Margin % | 1.46 | |||||
OCF Margin % | 5.75 | |||||
ROE % | 7.46 | |||||
ROA % | 5.49 | |||||
ROIC % | 5.45 | |||||
3-Year ROIIC % | -4.79 | |||||
ROC (Joel Greenblatt) % | 9.95 | |||||
ROCE % | 9.55 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 22.67 | |||||
PE Ratio without NRI | 21.26 | |||||
Shiller PE Ratio | 19.51 | |||||
PEG Ratio | 19.33 | |||||
PS Ratio | 1.28 | |||||
PB Ratio | 1.62 | |||||
Price-to-Tangible-Book | 1.68 | |||||
Price-to-Free-Cash-Flow | 87.82 | |||||
Price-to-Operating-Cash-Flow | 22.26 | |||||
EV-to-EBIT | 16.56 | |||||
EV-to-EBITDA | 10.69 | |||||
EV-to-Revenue | 1.36 | |||||
EV-to-FCF | 89.66 | |||||
Price-to-GF-Value | 0.98 | |||||
Price-to-Projected-FCF | 1.54 | |||||
Price-to-DCF (Earnings Based) | 2.13 | |||||
Price-to-DCF (FCF Based) | 9.77 | |||||
Price-to-Median-PS-Value | 1.13 | |||||
Price-to-Graham-Number | 1.19 | |||||
| Price-to-Net-Current-Asset-Value | 4.07 | |||||
Earnings Yield (Greenblatt) % | 6.04 | |||||
FCF Yield % | 1.11 | |||||
Forward Rate of Return (Yacktman) % | 2.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mercury Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 737.645 | ||
| EPS (TTM) (₹) | 34.69 | ||
| Beta | 1.0551 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.15 | ||
| Volatility % | 20.18 | ||
| 14-Day RSI | 50.82 | ||
| 14-Day ATR (₹) | 38.203036 | ||
| 20-Day SMA (₹) | 815.7625 | ||
| 12-1 Month Momentum % | -11.03 | ||
| 52-Week Range (₹) | 620.55 - 976 | ||
| Shares Outstanding (Mil) | 1.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mercury Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mercury Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 3.500000 Cash Dividend | 2026-09-18 | In 44 days | ||
| INR 3.500000 Cash Dividend | 2025-08-06 | 869.90 (-3.34%) | ||
| INR 3.500000 Cash Dividend | 2024-09-20 | 1,000.45 (-6.85%) |
Show
Entries
Mercury Laboratories Ltd Frequently Asked Questions
What is Mercury Laboratories Ltd(BOM:538964)'s stock price today?
The current price of BOM:538964 is ₹812.50. The 52 week high of BOM:538964 is ₹976.00 and 52 week low is ₹620.55.
When is next earnings date of Mercury Laboratories Ltd(BOM:538964)?
The next earnings date of Mercury Laboratories Ltd(BOM:538964) is .
Does Mercury Laboratories Ltd(BOM:538964) pay dividends? If so, how much?
The Dividend Yield %  of Mercury Laboratories Ltd(BOM:538964) is 0.45% (As of Today), Highest Dividend Payout Ratio of Mercury Laboratories Ltd(BOM:538964) was 0.13. The lowest was 0.06. And the median was 0.07. The  Forward Dividend Yield % of Mercury Laboratories Ltd(BOM:538964) is 0.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Mercury Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers